Is there a target value for time in tight range for individuals with type 1 diabetes on MDI? Data from masked CGM.

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM Expert Review of Endocrinology & Metabolism Pub Date : 2024-09-05 DOI:10.1080/17446651.2024.2400487

Takayuki Ohno, Daisuke Tsujino, Rimei Nishimura

{"title":"Is there a target value for time in tight range for individuals with type 1 diabetes on MDI? Data from masked CGM.","authors":"Takayuki Ohno, Daisuke Tsujino, Rimei Nishimura","doi":"10.1080/17446651.2024.2400487","DOIUrl":null,"url":null,"abstract":"Objective: Time in Tight Range (TITR), defined as the percentage of time within the glucose range of 70 to 140 mg/dL, is anticipated to be challenging to maintain without causing hypoglycemia, especially in individuals with type 1 diabetes (T1D). This study aimed to investigate the TITR target value in individuals with T1D on multiple daily injections (MDI).Methods: The study included 101 individuals with T1D on MDI aged 15 to 75 who were hospitalized at Jikei University School of Medicine from September 2006 to November 2013 to conduct Continuous Glucose Monitoring (CGM). The cutoff values of TITR for predicting the attainment of GMI < 7.0%, and TBR < 4% were determined using Receiver Operating Characteristic (ROC) curves.Results: The TITR cutoff value was calculated to be 41% (sensitivity 81%, specificity 88%) and 40% (54%,72%) for predicting GMI < 7.0% and TBR < 4%.Conclusions: In individuals with T1D on MDI without devices capable of preventing hypoglycemia, it is recommended to target TITR at 40% to address the risk of increased hypoglycemia sufficiently.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2024.2400487","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Time in Tight Range (TITR), defined as the percentage of time within the glucose range of 70 to 140 mg/dL, is anticipated to be challenging to maintain without causing hypoglycemia, especially in individuals with type 1 diabetes (T1D). This study aimed to investigate the TITR target value in individuals with T1D on multiple daily injections (MDI).

Methods: The study included 101 individuals with T1D on MDI aged 15 to 75 who were hospitalized at Jikei University School of Medicine from September 2006 to November 2013 to conduct Continuous Glucose Monitoring (CGM). The cutoff values of TITR for predicting the attainment of GMI < 7.0%, and TBR < 4% were determined using Receiver Operating Characteristic (ROC) curves.

Results: The TITR cutoff value was calculated to be 41% (sensitivity 81%, specificity 88%) and 40% (54%,72%) for predicting GMI < 7.0% and TBR < 4%.

Conclusions: In individuals with T1D on MDI without devices capable of preventing hypoglycemia, it is recommended to target TITR at 40% to address the risk of increased hypoglycemia sufficiently.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对使用 MDI 的 1 型糖尿病患者而言，是否有时间在严格范围内的目标值？数据来自遮蔽式 CGM。

目标：在严格范围内的时间（TITR）是指血糖在 70 至 140 mg/dL 范围内的时间百分比，预计要在不引起低血糖的情况下保持这一数值具有挑战性，尤其是对于 1 型糖尿病（T1D）患者。本研究旨在调查每日多次注射（MDI）的 T1D 患者的 TITR 目标值：研究纳入了 2006 年 9 月至 2013 年 11 月期间在慈惠大学医学院住院并进行连续血糖监测（CGM）的 101 名使用 MDI 的 15 至 75 岁 T1D 患者。预测达到 GMI 的 TITR 临界值结果：经计算，TITR 临界值为 41%（灵敏度 81%，特异度 88%），预测 GMI 临界值为 40%（54%，72%）：对于使用 MDI 但没有预防低血糖装置的 T1D 患者，建议将 TITR 设为 40%，以充分应对低血糖增加的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Endocrinology & Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

4.80

自引率

0.00%

发文量

期刊介绍： Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.